Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Documentation

  • Home >
  • Investors & media >
  • Documentation
13 June 2019
General meetings

Attendance sheet Open in new window

21 May 2019
General meetings

BALO prior notification Open in new window

21 May 2019
General meetings

Explanatory Statement – 2019 General Meeting Open in new window

21 May 2019
General meetings

Nominees to the Board of Directors Open in new window

21 May 2019
General meetings

Share and voting rights statement Open in new window

21 May 2019
General meetings

Proxy Card Open in new window

21 May 2019
General meetings

Notice of General Meeting on June 11, 2019 Open in new window

21 May 2019
General meetings

Auditor’s report on resolution number 24 Open in new window

21 May 2019
General meetings

Auditor’s report on resolution number 23 Open in new window

21 May 2019
General meetings

Auditor’s report on resolutions number 20 to 22 and 25 Open in new window

  • View previous 9 articles
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page